Although the threat posed by antimicrobial resistance (AMR) in urinary tract infections (UTI) is well documented; significant knowledge gaps remain for most countries in Sub Saharan Africa. In this study, we aimed to describe the most common uropathogens in Eritrea. The magnitude, trends, and factors associated with AMR and multidrug-resistance (MDR) were also assessed. A retrospective record review of data (January 2010 – 2021) collected from all urine samples from patients from multiple treatment centers in Eritrea and analyzed at the microbiology department at the National Reference Laboratory (NHL) was undertaken. SPSS was used for statistical analysis, and Microsoft Excel was used to plot figures. A total of 2,999 isolates were recovered from 2010 to 2021. Of these, 91
BACKGROUND:Blood donor screening occasionally identifies individuals with high HBV surface antigen (HBsAg) levels despite undetectable or extremely low HBV DNA. Molecular basis and transfusion risk of this discordant profile remain unclear. STUDY DESIGN AND METHODS:Seventy-five blood donors with HBsAg >100 IU/mL and undetectable or very low HBV DNA (<6 IU/mL), including 39 ID-NAT-nonreactive, were investigated. HBV DNA was further assessed using a second ID-NAT assay, confirmatory PCR following virion concentration, and sequencing. Sequences were compared with those from genotype-matched high-viremia controls. Selected basic core promoter (BCP) and core mutations were introduced into 1.18-mer replication-competent Hepatitis B virus (HBV) plasmids to assess effects on extracellular virion-associated DNA production. RESULTS:Four (5%) samples were nonreactive by the two ID-NAT assays. HBV DNA was confirmed in all donors, often at unquantifiable levels, and all were anti-HBc positive. No consistent molecular signature was identified. Heterogeneous, case-specific mutations were detected in BCP, core, and PreS1, including variants predicted to affect pregenomic RNA transcription, encapsidation, or virion assembly, with no evidence of impaired polymerase activity. In vitro, selected BCP mutations significantly reduced extracellular HBV DNA without affecting HBsAg production. Most core mutations had minimal impact, although two strains carrying cN92T/cM93T or cS170F showed reduced virion-associated DNA. Some constructs exhibited impaired virion secretion or increased naked capsid production. CONCLUSION:HBsAg-positive/low-DNA profile largely reflects chronic inactive infection with minimal viremia. Diverse regulatory and structural mutations may contribute in a multifactorial manner. Persistent viral genomes and residual replication support continued HBsAg screening where NAT sensitivity is suboptimal and anti-HBc testing cannot be implemented.
BACKGROUND:Sickle cell nephropathy (SCN) is a major chronic complication of sickle cell disease, and its progression may be influenced by genetic factors. This study aimed to investigate the association between variants in the MYH9 and BMPR1B genes and increased total proteinuria in patients with sickle cell anemia. MATERIALS AND METHODS:This cross-sectional study included patients with homozygous (SS) sickle cell disease who were followed up in Dakar. Urinary albumin, total proteins, and creatinine levels, along with serum creatinine and urea concentrations, were measured. Genotyping of the single nucleotide variants MYH9-rs4821469, MYH9-rs3752462, MYH9-rs2032487, and BMPR1B-rs17022863 was performed using mass spectrometry (MassARRAY technology). Associations were evaluated using multivariate logistic regression analysis. RESULTS:The 150-patient cohort had a mean age of 20.44 ± 9.86 years, with a slight female majority (51 %). A high prevalence of increased total proteinuria (urine proteins-to-creatinine ratio ≥150 mg/g) was observed, affecting 50.67 % of this young population. Multivariate analysis identified relative systemic hypertension (blood pressure ≥130/80 mmHg) as a powerful and independent risk factor for increased total proteinuria. While an initial analysis suggested a protective association for the MYH9 - rs4821469 variant, this signal was unstable and lost statistical significance in more stringent models. CONCLUSION:Increased total proteinuria is highly prevalent in this young cohort, indicating early onset of kidney damage. Relative systemic hypertension is a major modifiable risk factor, underscoring the need for rigorous blood pressure control. The instability of the initial genetic signal for MYH9-rs4821469, coupled with its strong linkage disequilibrium with APOL1, suggests that the observed association is likely confounded by ungenotyped APOL1 variants. This highlights the critical importance of including APOL1 analysis in future SCN genetic studies in African-ancestry populations.
An important knowledge gap exists on the epidemiology of blood stream infections (BSIs) in low-middle-income countries (LMICs). In this retrospective analysis, we evaluated the etiology, antimicrobial resistance (AMR) and trends of BSIs in Eritrea. The study reviewed 9-year records (January 2014– December 2022) of 3153 patients with blood culture results available in the National Health Laboratory (NHL) archives. Relevant data included age, sex, hospital/care center, and year. During the surveillance period, we examined data from 3153 patients (1797 (57.0
Cutaneous adverse events (cAEs) are among the most common toxicities associated with modern cancer therapies, which are particularly heightened among immunotherapies and targeted agents. Despite being frequently immune-mediated, the majority of cAEs are mild to moderate and can be effectively managed without interruption of anticancer treatment. In immunotherapies-receiving patients, common phenotypes of cAEs include eczema-like, lichenoid, psoriasiform, vitiligo-like, and bullous eruptions. Targeted therapies including epidermal growth factor receptor inhibitors, BRAF inhibitors/MEK inhibitors, and phosphoinositide 3-kinase inhibitors are frequently associated with papulopustular eruptions, xerosis, paronychia, and photosensitivity. Mechanistically, cAEs may result from on-target immune activation, which correlates with treatment efficacy, or off-target hypersensitivity. Notably, certain phenotypes such as vitiligo, alopecia areata, and lichenoid reactions have been associated with improved survival in melanoma and non-small cell lung cancer. Management is guided based on the Common Terminology Criteria for Adverse Events grading, emphasizing the role of topical therapies for mild cases, systemic corticosteroids or immunosuppressants for moderate-to-severe reactions, and biologic or novel topical agents for steroid-refractory disease. By timely and appropriate intervention, most cAEs are manageable and may carry favorable prognostic significance. Early dermatologic collaboration is essential to reduce morbidity and ensure uninterrupted oncologic therapy.